An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

{"level_sex_clusion_I":[{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Inclusion criteria: - Woman suffering from HER2+ early-stage Breast cancer (Stage I, stage IIA, stage IIB, or stage IIIA breast cancer); - Woman eligible for neoadjuvant or adjuvant HER2+ treatment, according to national guidelines; - Woman aged 18 years or older; - Woman having received oral and written information about the study, without any objections for the use of her personal data and having signed a written informed consent form. ","clusion_E":"Woman previously treated with Herceptin® subcutaneous;- Woman participating in a clinical trial assessing an anticancer treatment."}